Analysis of HLA-G 14 bp Insertion/Deletion Polymorphism and HLA-G, ILT2 and ILT4 Expression in Head and Neck Squamous Cell Carcinoma Patients DOI Creative Commons
Vladimı́ra Ďurmanová, Miroslav Tedla,

Dusan Rada

и другие.

Diseases, Год журнала: 2024, Номер 12(2), С. 34 - 34

Опубликована: Фев. 8, 2024

HLA-G is the checkpoint molecule involved in suppression of immune response. Increased expression and its ILTs receptors have been correlated with tumor progression various cancer types. In head neck squamous cell carcinoma (HNSCC) tumors, effect HLA-G, ILT2 ILT4 on development has to be explained. The 34 HNSCC patients 98 controls were genotyped for 14 bp ins/del polymorphism. lesions, mRNA was analysed using real-time PCR. association between clinical variables (age at onset, TNM staging system p16 positivity) also evaluated. No genetic risk detected (p > 0.05). However, non-metastatic group, a significantly higher noted tumors T4 stage compared those T1 T2 stages = 0.0289). increased vs. metastatic 0.0269). Furthermore, T1+T2 T3 0.0495). Our results suggest that creates an immunological microenvironment development.

Язык: Английский

Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer DOI Creative Commons

Amit Dey,

Abhijit Mitra, Surajit Pathak

и другие.

Technology in Cancer Research & Treatment, Год журнала: 2023, Номер 22

Опубликована: Янв. 1, 2023

Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile biomarkers associated with process considered personalized medicine, along patient's personal history. It is based on response targeted therapies specific genetic variations. transcriptomic epigenetic features evaluated, best therapeutic approach diagnostic testing identified through medicine. This review aims summarize necessary, updated information cancer related Personalized medicine gaining prominence as generalized treatments finding it challenging contain cases which currently rank fourth among global incidence while being fifth largest total death worldwide. In therapy, patients grouped into categories, chosen evaluating their molecular features. Various strategies explored treatment involving immunotherapy, phytochemicals, other biomarker-specific therapies. However, significant challenges must be overcome integrate healthcare systems completely. We look at various signaling pathways alterations understand identify useful therapy. current available improve existing methods discussed. highlights advantages limitations scenario developed countries faced middle- low-income also summarized. Finally, we discuss future perspectives how could integrated systems.

Язык: Английский

Процитировано

50
Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects DOI Creative Commons
Siyuan Wang, Jiaxin Wang, Yu Xia

и другие.

Journal of Translational Medicine, Год журнала: 2024, Номер 22(1)

Опубликована: Фев. 3, 2024

Abstract Immune checkpoint blockades have been prized in circumventing and ablating the impediments posed by immunosuppressive receptors, reaching an exciting juncture to be innovator anticancer therapy beyond traditional therapeutics. Thus far, approved immune principally targeted PD-1/PD-L1 CTLA-4 with success a plethora of tumors yet are still trapped dilemmas limited response rates adverse effects. Hence, unveiling new immunotherapeutic targets has aroused immense scientific interest hope expanding clinical application scale heights. Human leukocyte antigen-G (HLA-G), non-classical major histocompatibility complex (MHC) class I molecule, is enriched on various malignant cells involved hindrance effector facilitation cells. HLA-G stands out as crucial next-generation showing great promise for benefit cancer patients. Here, we provide overview current understanding expression pattern immunological functions HLA-G, well its interaction well-characterized checkpoints. Since can shed from cell surface or released free soluble (sHLA-G) part extracellular vesicles (EVs), namely HLA-G-bearing EVs (HLA-G EV ), discuss potential sHLA-G predictive biomarkers. This review also addresses advancement HLA-G-based therapies preclinical settings, focus their cancer.

Язык: Английский

Процитировано

10
Immunotherapy for colorectal cancer: insight from inherited genetics DOI
Nijole P. Tjader, Amanda E. Toland

Trends in cancer, Год журнала: 2024, Номер 10(5), С. 444 - 456

Опубликована: Фев. 14, 2024

Язык: Английский

Процитировано

6
Exploring the Role of KIR2DS4 and HLA-A*02:07 in Predicting Chemotherapy Sensitivity and Erythrocytopenia in Nasopharyngeal Carcinoma DOI Creative Commons
J. Ye, Haitao Ma,

Xue-Meng Jiang

и другие.

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Фев. 11, 2025

Abstract Background: Nasopharyngeal carcinoma (NPC) is common in Southeast Asia, with most patients diagnosed locally advanced disease. Radiotherapy alone often ineffective, so platinum-based chemotherapy combined for better outcomes. However, response and side effects vary among patients. Genetic markers, particularly human leukocyte antigen (HLA) killer-cell immunoglobulin-like receptors (KIR), have been implicated modulating sensitivity toxicity. Identifying these markers could facilitate personalized treatment strategies NPC Methods: This study included 204 between April 2020 October 2021, performed KIR HLA-A allele typing. The control group consisted of 201 healthy individuals, matched by gender age, who underwent routine health check-ups at the hospital. Among cases, 110 nasopharyngeal received platinum based were analyzed relationship HLA genotype characteristics sensitivity, as well occurrence induced effects. Results: exhibited higher expression activating KIR2DS4 (97.55% vs 91.54%, OR = 3.677, 95% CI 1.320 ~ 10.168, P 0.008) inhibitory KIR3DL1 93.03%, 2.980, 1.053 8.434, P 0.032), suggesting their involvement BB haplotype, a particular gene combination, was less frequent patients, hinting protective effect (4.90% 11.44%, 0.399, 0.185 0.861, 0.016). detection frequency HLA-A*11:01 case significantly lower than that (23.53% 30.71%, 0.694, 0.505 0.955, 0.024), HLA-A*02:07 (17.16% 8.70%, 2.175, 1.394 3.392, < 0.001). Notably, associated increased (51.35% 21.91%, 3.760, 1.552 8.648, 0.002). Additionally, KIR2DS4*003 linked to reduced incidence chemotherapy-induced erythrocytopenia (2.63% 97.37% non-carriers, 0.135, 0.017 1.082, 0.032). Conclusions: Our findings suggest are promising genetic predicting risk These results support potential regimens on profiling, helping reduce improve efficacy.

Язык: Английский

Процитировано

0
Analysis of HLA-G 14 bp Insertion/Deletion Polymorphism and HLA-G, ILT2 and ILT4 Expression in Head and Neck Squamous Cell Carcinoma Patients DOI Creative Commons
Vladimı́ra Ďurmanová, Miroslav Tedla,

Dusan Rada

и другие.

Diseases, Год журнала: 2024, Номер 12(2), С. 34 - 34

Опубликована: Фев. 8, 2024

HLA-G is the checkpoint molecule involved in suppression of immune response. Increased expression and its ILTs receptors have been correlated with tumor progression various cancer types. In head neck squamous cell carcinoma (HNSCC) tumors, effect HLA-G, ILT2 ILT4 on development has to be explained. The 34 HNSCC patients 98 controls were genotyped for 14 bp ins/del polymorphism. lesions, mRNA was analysed using real-time PCR. association between clinical variables (age at onset, TNM staging system p16 positivity) also evaluated. No genetic risk detected (p > 0.05). However, non-metastatic group, a significantly higher noted tumors T4 stage compared those T1 T2 stages = 0.0289). increased vs. metastatic 0.0269). Furthermore, T1+T2 T3 0.0495). Our results suggest that creates an immunological microenvironment development.

Язык: Английский

Процитировано

2